Delivery Order SPE2DB22D3004-SPE2DB25FRV54
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with completion targeted for August 12, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp for the supply of TEZSPIRE 210 MG/1.91 ML pen injectors, with an ultimate completion date of August 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded on August 4, 2025. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order represents a task under AmerisourceBergen's...
- The Defense Department's Medical Supply Chain awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. This is a firm fixed price, non-competitive delivery order with an ultimate completion date of August 18, 2025, to be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract supports federal pharmaceutical procurement requirements for military and veteran...
- The Defense Logistics Agency awarded a $14,061.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors, with an ultimate completion date of August 8, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen auto-injectors, with an ultimate completion date of August 22, 2025. This non-set-aside, competitively awarded contract represents a firm fixed price delivery order for pharmaceutical products to support federal medical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectables, with an ultimate completion date of August 21, 2025. This competitive award, issued on July 31, 2025, utilizes a firm fixed price contract structure with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $2,343.59 by the Defense Logistics Agency (DLA) for the supply of Tezspire 210 mg/1.91 mL pen injectors. This competitive, firm fixed-price contract carries an ultimate completion date of August 22, 2025, and was executed on August 1, 2025. The contract involves no set-aside designation and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical....
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order for Tezspire 210 mg/1.91 mL pen auto-injectors valued at $4,687.18 on July 25, 2025. This firm fixed-price contract, with completion scheduled for August 15, 2025, represents a non-set-aside, competitively awarded delivery order issued against AmerisourceBergen's existing indefinite delivery contract vehicle. The pharmaceutical product will be delivered to the contractor's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pen injectors on July 24, 2025, with completion targeted for August 14, 2025. This firm fixed-price contract is non-set-aside and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the federal government. This award is...
- The Defense Logistics Agency awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 12, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The product will support federal medical procurement needs for military and veteran healthcare systems. This...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FRV54Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,343.59, with a completion date of August 26, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply requirements. The work will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen Drug Corp supplies a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The parent IDC serves as a global pharmaceutical support vehicle enabling the company to fulfill diverse medical commodity needs across multiple therapeutic domains for customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/5/25 |